GlaxoSmithKline Pharmaceuticals share news and announcements
NSE: GLAXOBSE: 500660Pharmaceuticals & BiotechnologyMid Cap
Formerly Glaxo (India)
Last close ₹2,404.70down ₹29.00 (1.19%)BSE ₹2,404.80
Share price at the NSE close on 23 Oct 2026. Previous close ₹2,433.70.
52-week range of traded prices to 23 Oct 2026
₹2,088.10Low, 12 Jun 2026₹3,120.70High, 28 Aug 2026
- Next results date: the board meets on 3 Nov 2026 to consider: financial results.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹40,737 Cr221st largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 3 Aug 2026
- 38.1
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 13 May 2026
- 18.0
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- 2.37%
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 3 Aug 2026
- 50.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 3 Aug 2026
- 56.3%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 13 May 2026
- 0.00
- Volume, NSEVolume. Shares traded on the last trading day; delivery is the part buyers kept rather than sold again the same day.
- 56,17458.6% delivered
GlaxoSmithKline Pharmaceuticals board meetings
114 filed, newest first. Page 2 of 3.
Jun 2019
May 2019
20 May · Board meeting
Apr 2019
Mar 2019
28 Mar · Board meeting
Feb 2019
4 Feb · Board meeting
Dec 2018
Oct 2018
22 Oct · Board meeting
22 Oct · Board meeting
Sep 2018
Jul 2018
24 Jul · Board meeting
Jun 2018
May 2018
Apr 2018
Dec 2017
Oct 2017
Jun 2017
May 2017
19 May · Board meeting
Jan 2017
Oct 2016
Jul 2016
May 2016
Jan 2016
Oct 2015
Jul 2015
Jun 2015
May 2015
Feb 2015
Jan 2015
Oct 2014
9 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2014.
Jul 2014
Apr 2014
Jan 2014
Oct 2013
25 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2013.
Jul 2013
22 Jul · Board meeting
Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2013 (Q2) and half-year January-June 2013.
Apr 2013
25 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2013.2 Apr · Board meeting
To consider and approve re-constitution and adopt the terms of references of the following Sub-Committees of the Board : (1) Audit Committee; (2) Investor Grievance Committee; (3) Remuneration Committee.
Feb 2013
4 Feb · Board meeting
Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2012 and to recommend dividend, if any, on the equity shares of the Company.
Oct 2012
18 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2012.
Aug 2012
1 Aug · Board meeting
Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2012 (Q2) and half-year January-June 2012.
Apr 2012
27 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2012.
Feb 2012
10 Feb · Board meeting
Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2011 and to recommend dividend, if any, on the equity shares of the Company.
Oct 2011
19 Oct · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2011.
Jul 2011
22 Jul · Board meeting
Inter-alia, to consider amongst other things, approval of unaudited financial results for the quarter April-June 2011 (Q2) and half-year January-June 2011.
Apr 2011
28 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2011
Feb 2011
1 Feb · Board meeting
Inter-alia, to consider amongst other things, approval of audited financial results for the year ended December 31, 2010 and to recommend dividend, if any, on the equity shares of the Company.
Oct 2010
12 Oct · Board meeting
To Consider amongst other things, approval of unaudited financial results for the quarter ended September 30, 2010.
Jul 2010
8 Jul · Board meeting
Interalia, to consider amongst other things, approval of unaudited financial results for the 2nd Quarter April-June 2010 & Half-year ended June 30, 2010.
Apr 2010
20 Apr · Board meeting
To consider amongst other things, approval of unaudited financial results for the quarter ended March 31, 2010.